All News

There are more than 36 million smokers in the United States today, and most (70%) admit they want to quit. Individuals who decide to quit see a smaller risk of heart disease within 1 to 2 years, along with reduced risks of stroke and peripheral vascular disease. However, annual deaths from smoking still exceed 480,000 in the United States, where over 16 million live with smoking-related diseases that include infertility, lung cancer, and chronic obstructive pulmonary disease.

In-home noninvasive positive pressure ventilation via bilevel positive airway pressure devices exhibited lower risk of mortality, fewer patients with all-cause hospital admission, and less need for intubation, but had no significant difference in quality-of-life for patients with chronic obstructive pulmonary disease (COPD) and hypercapnia, according to study findings.

This week, top managed care stories included survey results on oncology practices’ willingness to take on risk; a warning of flu among children in detention centers; study findings establishing a link between circadian rhythm and type 2 diabetes.

When effectively integrated into healthcare systems, well-vetted and scientifically backed healthcare quality measures can have significant impacts on patient health, stressed Shantanu Agrawal, MD, president and CEO of the National Quality Forum, at the New Jersey Health Care Quality Institute’s Quality Breakfast on February 6.

The Patent Trial and Appeals Board delivered a setback to Gilead Sciences, rejecting its attempt to invalidate a pair of Truvada patents owned by the CDC; Merck is spinning off some businesses in order to focus on its oncology drug pembrolizumab, including its biosimilars operations; Republican and Democratic governors are worried that a proposed CMS fiscal accountability rule for Medicaid will reduce access to healthcare.

Anti-CD19 chimeric antigen receptor natural killer (CAR NK) cells, derived from donor umbilical cord blood, produced a 73% objective response rate in 11 patients with lymphoid tumors who received just 1 dose of the infused therapy, with no occurrences of cytokine release syndrome or neurotoxicity, in preliminary study results out of MD Anderson. Seven patients had a complete remission.

Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo